Emmaus Life Sciences, Inc. (Nasdaq: EMMA), a leader in sickle cell disease treatment, today reported significantly improved financial results at its EMI Holding, Inc. (EMI) subsidiary for the 2019 second quarter and six-months ended June 30, 2019
August 12, 2019
· 9 min read